miltefosine has been researched along with American Trypanosomiasis in 19 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Trypanosoma cruzi, the Chagas disease etiological agent, is sensitive to APs (edelfosine, miltefosine and ilmofosine) in vitro." | 3.91 | In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects. ( Barrias, E; Calogeropoulou, T; de Souza, W; Reignault, LC, 2019) |
| "We have previously shown that 3-nitro-1H-1,2,4-triazole-based arylamides and arylsulfonamides demonstrate significant activity in vitro against Trypanosoma cruzi, the causative parasite of Chagas disease." | 3.80 | Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. ( Bloomer, WD; Kaiser, M; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR, 2014) |
| "Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol." | 2.47 | Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011) |
| "Chagas Disease is caused by infection with the insect-transmitted protozoan Trypanosoma cruzi and affects more than 10 million people." | 1.51 | Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model. ( Costa, A; López, C; Marín, C; Martín-Escolano, R; Martin-Montes, Á; Medina-Carmona, E; Rotger, C; Sánchez-Moreno, M; Vega, M, 2019) |
| " This alkylphospholipid was also extremely toxic against intracellular amastigotes of both strains." | 1.31 | Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. ( Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Boiani, M | 1 |
| Boiani, L | 1 |
| Merlino, A | 1 |
| Hernández, P | 1 |
| Chidichimo, A | 1 |
| Cazzulo, JJ | 1 |
| Cerecetto, H | 1 |
| González, M | 1 |
| Papadopoulou, MV | 5 |
| Trunz, BB | 1 |
| Bloomer, WD | 5 |
| McKenzie, C | 1 |
| Wilkinson, SR | 5 |
| Prasittichai, C | 1 |
| Brun, R | 3 |
| Kaiser, M | 7 |
| Torreele, E | 1 |
| Patrick, DA | 1 |
| Ismail, MA | 1 |
| Arafa, RK | 1 |
| Wenzler, T | 1 |
| Zhu, X | 1 |
| Pandharkar, T | 1 |
| Jones, SK | 1 |
| Werbovetz, KA | 1 |
| Boykin, DW | 1 |
| Tidwell, RR | 1 |
| Rosenzweig, HS | 4 |
| O'Shea, IP | 2 |
| Chatelain, E | 2 |
| Ioset, JR | 1 |
| Szular, J | 1 |
| Linciano, P | 1 |
| Moraes, CB | 1 |
| Alcantara, LM | 1 |
| Franco, CH | 1 |
| Pascoalino, B | 1 |
| Freitas-Junior, LH | 1 |
| Macedo, S | 1 |
| Santarem, N | 1 |
| Cordeiro-da-Silva, A | 1 |
| Gul, S | 1 |
| Witt, G | 1 |
| Kuzikov, M | 1 |
| Ellinger, B | 1 |
| Ferrari, S | 1 |
| Luciani, R | 1 |
| Quotadamo, A | 1 |
| Costantino, L | 1 |
| Costi, MP | 1 |
| Thompson, AM | 1 |
| O'Connor, PD | 1 |
| Marshall, AJ | 1 |
| Blaser, A | 1 |
| Yardley, V | 2 |
| Maes, L | 3 |
| Gupta, S | 1 |
| Launay, D | 1 |
| Braillard, S | 1 |
| Wan, B | 1 |
| Franzblau, SG | 1 |
| Ma, Z | 1 |
| Cooper, CB | 1 |
| Denny, WA | 1 |
| Saccoliti, F | 1 |
| Madia, VN | 1 |
| Tudino, V | 1 |
| De Leo, A | 1 |
| Pescatori, L | 1 |
| Messore, A | 1 |
| De Vita, D | 1 |
| Scipione, L | 1 |
| Mäser, P | 1 |
| Calvet, CM | 1 |
| Jennings, GK | 1 |
| Podust, LM | 1 |
| Costi, R | 1 |
| Di Santo, R | 1 |
| Martín-Escolano, R | 1 |
| Marín, C | 1 |
| Vega, M | 1 |
| Martin-Montes, Á | 1 |
| Medina-Carmona, E | 1 |
| López, C | 1 |
| Rotger, C | 1 |
| Costa, A | 1 |
| Sánchez-Moreno, M | 1 |
| Wang, X | 1 |
| Cal, M | 1 |
| Buckner, FS | 1 |
| Lepesheva, GI | 1 |
| Sanford, AG | 1 |
| Wallick, AI | 1 |
| Davis, PH | 1 |
| Vennerstrom, JL | 1 |
| Bouton, J | 1 |
| Ferreira de Almeida Fiuza, L | 1 |
| Cardoso Santos, C | 1 |
| Mazzarella, MA | 1 |
| Soeiro, MNC | 2 |
| Karalic, I | 2 |
| Caljon, G | 2 |
| Van Calenbergh, S | 2 |
| Lin, C | 1 |
| Jaén Batista, DDG | 1 |
| Mazzeti, AL | 1 |
| Donola Girão, R | 1 |
| de Oliveira, GM | 1 |
| Hulpia, F | 1 |
| Gulin, JEN | 1 |
| Bisio, MMC | 1 |
| Rocco, D | 1 |
| Altcheh, J | 1 |
| Solana, ME | 1 |
| García-Bournissen, F | 1 |
| Barrias, E | 1 |
| Reignault, LC | 1 |
| Calogeropoulou, T | 1 |
| de Souza, W | 1 |
| Benaim, B | 1 |
| Garcia, CR | 1 |
| Saraiva, VB | 1 |
| Gibaldi, D | 1 |
| Previato, JO | 1 |
| Mendonça-Previato, L | 1 |
| Bozza, MT | 1 |
| Freire-De-Lima, CG | 1 |
| Heise, N | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
1 review available for miltefosine and American Trypanosomiasis
| Article | Year |
|---|---|
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman | 2011 |
18 other studies available for miltefosine and American Trypanosomiasis
| Article | Year |
|---|---|
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
Topics: Animals; Benzimidazoles; Cell Line; Cell Survival; Chagas Disease; Glucose; Leishmania braziliensis; | 2009 |
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
Topics: Amines; Animals; Cells, Cultured; Chagas Disease; Leishmania donovani; Mice; Nitro Compounds; Parasi | 2011 |
Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
Topics: Animals; Antiprotozoal Agents; Benzene; Chagas Disease; Female; Leishmania donovani; Mice; Mice, Inb | 2013 |
Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
Topics: Amides; Apoptosis; Blood Platelets; Cells, Cultured; Chagas Disease; Flow Cytometry; Heterocyclic Co | 2014 |
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line; Chagas Disease; Disease Models, Animal; Leishmania donovani; Mice | 2015 |
3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
Topics: Animals; Cell Line; Chagas Disease; Dose-Response Relationship, Drug; Humans; Leishmania donovani; M | 2015 |
Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
Topics: Amides; Antiprotozoal Agents; Cell Line; Chagas Disease; Humans; Leishmania; Parasitic Sensitivity T | 2016 |
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
Topics: Antiprotozoal Agents; Chagas Disease; Dose-Response Relationship, Drug; Humans; Macrophages; Molecul | 2018 |
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
Topics: Animals; Antiparasitic Agents; Cell Membrane Permeability; Chagas Disease; Cricetinae; Cytochrome P- | 2018 |
Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Chagas Disease; Female; Humans; Imidazoles; Inhibitory Con | 2018 |
Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
Topics: Animals; Chagas Disease; Chlorocebus aethiops; Cyclobutanes; DNA; Female; Membrane Potential, Mitoch | 2019 |
A new chemotype with promise against Trypanosoma cruzi.
Topics: Animals; Chagas Disease; Humans; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma c | 2020 |
Revisiting Pyrazolo[3,4-
Topics: Animals; Chagas Disease; Drug Design; Drug Stability; Humans; Leishmania infantum; Male; Mice; Micro | 2021 |
N
Topics: Animals; Chagas Disease; Leishmania; Mice; Nucleosides; Purines; Structure-Activity Relationship; Tr | 2022 |
Miltefosine and Benznidazole Combination Improve Anti-
Topics: Animals; Chagas Disease; Mice; Nitroimidazoles; Parasitemia; Phosphorylcholine; Trypanocidal Agents; | 2022 |
In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects.
Topics: Adamantane; Animals; Antiprotozoal Agents; Autophagy; Cell Membrane; Chagas Disease; Dose-Response R | 2019 |
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Drug Resistance; Exudates and Transudates; Inflammati | 2002 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |